Nuclear medicine, made clear.
nucmed.net is an online platform dedicated to nuclear medicine education. The ultimate goal is to create a dynamic, comprehensive and interactive resource of molecular imaging and theranostics.
Cases →
Large vessel vasculitis
by Nazim Coskun
Septic embolism (infective endocarditis)
by Nazim Coskun
Transthyretin cardiac amyloidosis
by Nazim Coskun
Male breast cancer (FDG)
by Nazim Coskun
Squamous cell carcinoma of the lung
by Nazim Coskun
Desmoid tumor
by Nazim Coskun
Splenic hemangioma
by Nazim Coskun
Sinonasal melanoma
by Nazim Coskun
Recent Bookmarks →
A hand-crafted list of notable publications and news in the field of nuclear medicine and theranostics.
Transarterial Radioembolization Can Downstage Intermediate and Advanced Hepatocellular Carcinoma to Liver Transplantation
TARE allows for a 44% chance of response, 30% downstaging, and 23% probability of permitting liver transplantation in intermediate and advanced HCC.
journals.lww.comEvaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary
18F-FDG PET/CT plays a complementary role in CUP diagnostic work-up and was able to determine the likely primary site in 41% of cases. OS is improved with primary site identification, demonstrating the value of access to diagnostic 18F-FDG PET/CT for CUP patients.
jnm.snmjournals.orgThe LUTADOSE trial: tumour dosimetry after the first administration predicts PFS in GEP NET patients treated with 177Lu-DOTATATE
Patients with a mean tumour absorbed dose lower than the best cut-off value of 10.6 Gy after first cycle had a significantly shorter median PFS (HR 8.6, 95% CI: 2–37).
link.springer.comPrognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer
Salvage RT is associated with delayed clinical progression in patients with post radical prostatectomy biochemical recurrence and negative PSMA PET/CT (HR: 0.2, p=0.03). Median follow-up was 39 months.
pubmed.ncbi.nlm.nih.gov
Clinical Trials →
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Phase 2 • Updated on Dec 6, 2024
Comparing Retreatment of 177Lu-DOTATATE PRRT versus Everolimus in Patients with Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Phase 2 • Updated on Dec 6, 2024
Phase I Study of [177Lu]Lu-NNS309 in Patients with Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 • Updated on Dec 6, 2024